Resources from the same session
Personalized drug therapy for mesothelioma: Do we have enough targets?
Presenter: Alessandra Curioni-Fontecedro
Session: ETOP-IBCSG: Areas under investigation
Resources:
Slides
Webcast
Emerging strategies to overcome osimertinib resistance
Presenter: Ross Soo
Session: ETOP-IBCSG: Areas under investigation
Resources:
Slides
Webcast
Strategies to improve KRAS inhibition
Presenter: Maurice Perol
Session: ETOP-IBCSG: Areas under investigation
Resources:
Slides
Webcast
Lung cancer biomarker harmonisation and validation: Insights from the ETOP Translation Group
Presenter: Stephen Finn
Session: ETOP-IBCSG: Areas under investigation
Resources:
Slides
Webcast